A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
About the study
This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Aged ≥ 18 years;
- Diagnosis of clinically moderate to severe plaque-psoriasis;
- Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
- Patient agrees to sign the informed consent
EXCLUSION CRITERIA
Exclusion Criteria:
- Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Psoriasis
Age (in years)
18 - 100
Participants needed
1002
Est. Completion Date
Dec 30, 2023
Treatment type
Observational
Sponsor
Novartis
ClinicalTrials.gov identifier
NCT04894890
Study number
CAIN457ACN06
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?